Combined antiviral treatment in HIV infection. Is it value for money?

Public Health

Volumn 113, Issue 6, 1999, Pages 315-317

  Davies, D ^a,c   Carne, C ^b   Camilleri Ferrante, C ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^c Bedfordshire Health ^*  (United Kingdom)

Author keywords

Combined drug therapy; Economic health costs; HIV; Monodrug therapy; Protease inhibitors; Reverse transcriptase inhibitors

Indexed keywords

DIDANOSINE; RITONAVIR; ZIDOVUDINE;

ARTICLE; HEALTH CARE COST; HOSPITAL COST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MORBIDITY; MORTALITY;

EID: 0033382072     PISSN: 00333506     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.ph.1900594     Document Type: Article

References (19)

1. BHVA Guidelines Coordinating Committee. British HIV Association guidelines for antiviral treatment of HIV seropositive individuals. Lancet 1997; 349: 1086-1092.
2. Davies D, Camilleri-Ferrante C. The clinical and cost effectiveness of combination drug therapies in Human Immunodeficiency Virus infection. 46. Anglia Clinical Audit and Effectiveness Team (ACET): Cambridge, 1997.
3. + lymphocytes in HIV-1 infection. Nature 1995; 373: 123-126.
4. Ho D. Viral counts count in HIV infection. Science 1996; 272: 1124-1125.
5. Fischl M, et al. The efficacy of azidothymidine (zidovudine) in the treatment of patients with AIDS and AIDS-related complex. N Engl J Med 1987; 317: 185-191.
6. Volberding PA et al. Zidovudine in asymptomatic human immunodeficiency virus infection. New Engl Med 1990; 322: 941-949.
7. Volberding P et al. The duration of zidovudine benefit in persons with asymptomatic HIV infection. Prolonged evaluation of protocol 019 of the AIDS Clinical Trials Group. J Am Med Assoc 1994; 272: 437-442.
8. Kahn et al. A controlled trial comparing continued zidovudine with didanosine in human immunodeficiency virus infection. N Engl J Med 1992; 327: 581-587.
9. D'Aquila R et al. Zidovudine resistance and HIV-1 disease progression during antiretroviral therapy. AIDS Clinical Trials Group Protocol 116B/117 Team and the Virology Committee Resistance Working Group. Ann Intern Med 1995; 122: 401-408.
10. Volberding P et al. A comparison of immediate with deferred zidovudine therapy for asymptomatic HIV-infected adults with CD4 cell counts of 500 or more per cubic millimeter. N Engl J Med 1995; 333: 401-407.
11. Abrams et al. A comparative trial of didanosine or zalcitabine after treatment with zidovudine in patients with human immunodeficiency virus infection. N Engl J Med 1994; 330: 657-662.
12. Delta Coordinating Committee. Delta: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Lancet 1996; 348: 283-291.
13. + cell counts from 200 to 500 per cubic milliliter. N Engl J Med 1996; 335: 1081-1090.
14. CAESAR Coordinating Committee. Randomised trial of addition of lamivudine or lamivudine plus loviride to zidovudine-containing regimens for patients with HIV-1 infection: the CAESAR trial. Lancet 1997; 349: 1413-1421.
15. Nageswaran A, Kinghorn G, Shen R, Priestley CJ, Kyi T. Hospital service utilization by HIV/AIDS patients and their management cost in a provincial genitourinary medicine department. Int J Sex Trans Dis AIDS 1995; 6: 336-344.
16. British National Formulary British Medical Association and The Pharmaceutical Press: London, 1998.
17. Beck E, Kupek E, Wadsworth J, Miller D, Pinching A, Harris J. The use and cost of hospital services by London AIDS patients with different AIDS defining conditions. J Publ Health 1996; 18: 457-464.
18. Chancellor J, Hill A, Sabin C, Simpson K, Youle M. Modelling the cost effectiveness of lamivudine/zidovudine combination therapy in HIV infection. Pharmacoeconomics 1997; 12: 54-56.
19. Gazzard B, Moyle G. 1998 revision to the British HIV Association guidelines for anti-retroviral treatment of HIV seropositive individuals. Lancet 1998; 350: 314-316.